N
BMY icon

Nuveen’s Bristol-Myers Squibb BMY Stock Holding History

Nuveen’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500,000
Closed -$36K – 3190
2022
Q3 		$36K Buy
+500,000
New +$36.3M ﹤0.01% 3174

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen's BMY Position: Q1 2026 in Review

Nuveen increased its Bristol-Myers Squibb (BMY) stake by 5.2% in Q1 2026, buying an estimated $16.8M and bringing the position to 5,813,633 shares worth $353M. The position accounts for 0.1% of the portfolio, ranked #168.

Nuveen first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.37B in Q4 2019. 2,525 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Nuveen held 5,813,633 shares of Bristol-Myers Squibb worth $353M as of Q1 2026.
  • Nuveen bought 287,372 Bristol-Myers Squibb shares in Q1 2026, an estimated $16.8M.
  • Bristol-Myers Squibb made up 0.1% of Nuveen's portfolio in Q1 2026, its #168 holding.
  • Nuveen first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Nuveen's Bristol-Myers Squibb position peaked at $1.37B in Q4 2019.
  • 2,525 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.